FOXO4-DRI: A Retro-Inverso Senolytic Peptide

Research summary. FOXO4-DRI (Drug Retro-Inverso) is a synthetic D-amino-acid peptide designed to selectively induce apoptosis in senescent cells. The molecule was developed in the laboratory of Peter de Keizer and reported in Cell in 2017 in a study that became one of the most-cited references in the senolytic-peptide field. Its mechanism centres on disrupting a specific protein–protein interaction between FOXO4 and p53 that protects senescent cells from apoptotic clearance.

Molecular profile

• Sequence: A D-amino-acid retro-inverso analogue of the FOXO4 segment that engages p53, conjugated to a D-amino-acid TAT cell-penetration sequence
• Molecular weight: ~5358 g/mol
• Class: Cell-penetrating retro-inverso peptide (senolytic)
• Synonyms: Proxofim (development name in some pre-clinical-translation contexts)

The "DRI" in the name stands for D-amino-acid Retro-Inverso. Retro-inverso engineering reverses the linear sequence order of the peptide and substitutes each L-amino-acid for its D-isomer. Because the side-chain spatial orientation is approximately preserved, retro-inverso peptides can retain target binding while gaining substantial protease resistance, since standard mammalian proteases cannot efficiently cleave D-amino-acid bonds.

Mechanism of action

Senescent cells are non-dividing cells that have entered a permanent growth-arrested state characterised by elevated p53/p21 and p16 signalling, together with a senescence-associated secretory phenotype (SASP) that drives chronic low-grade inflammation. A central paradox of cellular senescence is that these cells are resistant to apoptosis, despite expressing high levels of pro-apoptotic p53 — they remain alive and metabolically active for prolonged periods.

The Baar et al. 2017 study identified that, in senescent cells, the transcription factor FOXO4 binds and sequesters p53 in the nucleus, preventing it from triggering its apoptotic transcriptional programme. FOXO4-DRI was designed as a competitive peptide that disrupts this FOXO4–p53 interaction. Liberated p53 then transitions from a chronic growth-arrest signal to an acute apoptotic signal — but selectively in cells where the FOXO4–p53 interaction is the dominant survival mechanism, i.e., senescent cells. Non-senescent cells, which do not depend on this interaction, are largely spared [1].

This selective induction of apoptosis in senescent cells is the defining feature of the senolytic class of compounds.

Preclinical research highlights

Aged mouse model. The foundational Baar study reported that systemic FOXO4-DRI administration to naturally aged mice produced reductions in markers of senescent cell burden, improvements in renal function (elevated glomerular filtration rate), restored fur density, and improved physical activity metrics. Improvements were reported on the order of weeks to months following intermittent dosing schedules consistent with the senolytic strategy of removing senescent cells rather than continuously suppressing their function.

Chemotherapy-induced senescence. In doxorubicin-treated mice (a chemotherapy-induced senescence model), FOXO4-DRI administration was reported to reduce senescent cell burden and attenuate chemotherapy-related fitness decline.

Cell-culture validation. In primary fibroblast and cancer-cell senescence-induction models, FOXO4-DRI was reported to selectively induce p53-dependent apoptosis in senescent cells while sparing proliferating and quiescent populations.

Healthspan vs lifespan. A consistently reported feature of the FOXO4-DRI work is that improvements were more pronounced in healthspan metrics (functional indicators of organ performance) than in absolute lifespan extension. This pattern is broadly consistent with other senolytic interventions in mice and is conceptually important: senescent-cell clearance appears to delay onset of age-related dysfunction more clearly than it extends maximum lifespan in the rodent models studied.

Why retro-inverso engineering matters here

FOXO4-DRI is one of the more elegant pharmacological applications of retro-inverso design in the published literature. Its target is an intracellular protein–protein interface, requiring both cell penetration (provided by the D-TAT segment) and resistance to intracellular proteolysis (provided by the D-amino-acid backbone). The combination produces a peptide with a half-life and intracellular activity sufficient for systemic in-vivo dosing — capabilities that an L-amino-acid version would lack.

Limitations and follow-up

• The body of in-vivo work on FOXO4-DRI is more limited than the foundational paper might suggest, and independent replication of the murine effects has been incremental rather than extensive.
• The molecule is a research compound; it has not entered formal clinical development as of the time of writing.
• The mechanism positions FOXO4-DRI as one of several senolytic strategies under investigation, alongside small-molecule senolytics (dasatinib + quercetin, fisetin, navitoclax/ABT-263) that target different anti-apoptotic pathways in senescent cells.
• Oral bioavailability is poor; subcutaneous or intravenous administration is required for in-vivo activity.

Current research status

FOXO4-DRI remains an investigational research peptide. It is widely used as a tool compound in senescent-cell biology research and is one of the canonical reference molecules in the senolytic literature. It has not been approved as a therapeutic agent and is not in formal clinical development.

Key takeaways for researchers

• FOXO4-DRI is a D-amino-acid retro-inverso peptide that disrupts the FOXO4–p53 interaction inside senescent cells, releasing p53 to trigger selective apoptosis.
• It is a senolytic, meaning it selectively eliminates senescent cells rather than blocking their formation or modulating their secretory phenotype.
• Reported preclinical effects centre on healthspan metrics in aged and chemotherapy-treated mice.
• It is an important reference compound in senescent-cell biology research.
• It is not an approved therapeutic.

References

1. Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169(1):132–147.e16.

---

This article is provided for educational and research purposes only. FOXO4-DRI is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.